- Sanofi SA's SNY Q3 sales grew 10.1% Y/Y to €10.4 billion due to solid growth from Dupixent, Vaccines, and Consumer Healthcare.
- EPS for the quarter increased 19.1% on reported and CER basis to €2.18.
- Sales from eczema treatment, Dupixent, jumped 54% to €1.41 billion.
- Vaccines sales increased 16.5% to €2.42 billion with record quarterly sales driven by flu vaccines and meningitis franchise recovery.
- Consumer Healthcare sales increased 11.1% to €1.16 billion, driven by the growth of Pain care and Digestive Wellness categories.
- The gross margin increased 1.9 percentage points to 72.8% versus the third quarter of 2020.
- Sanofi generated a free cash flow of €2.20 billion.
- Guidance: Sanofi now expects EPS to climb by around 14% at constant currencies for FY21, up from a previous, already improved estimate for 12% growth released in July.
- Read Next: Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism.
- Price Action: SNY shares traded higher by 0.69% at $49.91 premarket on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in